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Results:  The study population consisted of 206 patients treated 
with surgery and 136 patients treated with RT. Median follow up 
was 6.6 years. Patients in the surgical cohort were younger, with 
mean age: 48.9 versus 60.7 years, p < 0.001, and had larger 
tumours, with mean maximum dimension: 25.7 +/- 10.3 mm 
versus 20.3 +/- 6.6 mm, p < 0.001. After all VS treatments, the 
population’s PFS was 92.8 +/- 1.5% at five years and 83.7% +/- 
2.9% at 10 years. The population’s SH preservation at last follow 
up was 34.2%. SAEs occurred in 4.7% of patients. In the 
radiotherapy cohort of 136 patients, 17% had previous surgery 
(four complete resection, five planned subtotal resection and 14 
unplanned partial resection). Sixty-seven percent had single-
fraction stereotactic radiosurgery and 33% had fractionated 
stereotactic radiotherapy. Seven percent had progressive disease 
requiring salvage surgery. Eighteen percent had FND (HB Grade 
2 or more) at presentation. No patients had improvement in FND 
after RT and 17% had new or worsened FND after treatment. SAEs 
were: hydrocephalus requiring ventriculoperitoneal shunt 1.5%, 
radionecrosis 0.7%, hospitalization for steroid myopathy 0.7%, 
and death from complications of disease 0.7%. In the surgical 
cohort of 206 patients, 8% had previous treatment (eight 
radiation, nine surgery). The most common surgical approaches 
were retrosigmoid (89%) and translabyrinthine (6%). Two percent 
had planned post-op RT and 12% had disease progression 
requiring salvage: 19 RT, three surgery, two unknown. Twelve 
percent had FND at presentation. FND improved in 4.4% and 
worsened in 12.6% after surgery. SAEs were: increased 
intracranial pressure requiring external ventricular drain 2.9%, 
dural fistula requiring lumbar drain 1.5%, evacuation of 
hematoma 1.0%, and perioperative death 0.5%. 
Conclusions:  Multidisciplinary management of VS provides 
excellent disease control at a population level with hearing 
preservation in a minority of patients and a low-risk of serious 
adverse events. 
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Purpose: Conventional imaging methods, such as computed 
tomography (CT) and magnetic resonance imaging (MRI) are not 
as effective as magnetic resonance spectroscopy (MRS) in 
diagnosing, grading, and evaluating high-grade glioma (HGG) 
tumour response to treatment1. MRS uniquely determines 
whether tumour is viable or contains metabolic activity following 
post-operative radiotherapy (RT). This study’s preliminary data 
was published2, and has currently become the largest 
prospective trial to investigate the correlation between changes 
in MRS spectra in HGG patients before, during, and after post-
operative RT with overall survival (OS). 
Methods and Materials: Forty-four patients with histologically 
confirmed HGG prospectively completed surgery and RT to 6000 
cGy. MRS was performed prior to starting RT, during week 4 of 
RT, and at two months post-RT. Metabolite ratios of: 1) choline 
/ creatine; 2) NAA/creatine; and 3) choline/NAA were calculated 
from MRS spectra at each time point. Normalized metabolite 
ratios, defined as Tumour metabolite/Normal contralateral brain 
metabolite, were evaluated for differences in OS from baseline 
to post-RT. Kaplan-Meier curves of OS were analyzed for 
statistical significance by the log-rank method, and paired groups 
of metabolite ratios examining changes over time were 
compared using the paired t-test, with a significance value of α 
= 0.05. 
Results: After a median follow up of 21.0 months, mean 
normalized choline significantly decreased from baseline to two 
months post-RT (1.98 versus 1.35, p = 0.019). Patients with < 60% 
decrease in normalized choline from baseline to two months 
post-RT had a significantly better median OS (34.98 versus 10.49 
months, p = 0.049). Moreover, patients with any increase in 
normalized choline from baseline to week 4 of RT had 
significantly better median OS after completing RT (39.19 versus 
16.09 months, p = 0.037). 
Conclusions: This study is the largest prospective trial to 
demonstrate that changes in normalized choline from baseline to 
two months post-RT are highly predictive for OS. These 
prognostic MRS changes further strengthen the clinical use of 
advanced imaging techniques to improve the diagnostic and 
grading effectiveness of imaging, to noninvasively sample the 
molecular features of gliomas, to evaluate local tumour response 
to radiotherapy, and to optimize individualized treatments for 
patients with HGG. 
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Purpose: Rectal toxicity can be a significant consequence of 
prostate radiation therapy, and a number of different dosimetric 
parameters have been used with the intention of decreasing 
rectal toxicity. This has led to a wide array of retrospective trials 
wherein different definitions of the rectum led to variation in 
DVH (dose volume histogram) data. Compounding this, many 
dose escalation studies have been done in the last decade after 
a close relationship between local control and radiation dose was 
found. This resulted in a variety of DVH recommendations 
without clear consensus in the literature.  
Methods and Materials: As part of a quality assurance task, 
random data on 50 consecutive prostate cancer patients treated 
at our institution with rapid arc protocol was analyzed. Defined 
constraints were studied and evaluated: if they fulfilled organ at 
risk (OAR) limitations as per institutional protocol, or if some 
OAR constraints were too stringent. This included rectal V40 Gy 
< 55%, which has not been quoted in recent RTOG trials.  
Results: Rectal data analysis highlighted that V75 Gy < 15%, V70 
Gy < 20% and V60 Gy < 35% were achieved in all patients. V65 Gy 
< 25% and V50 Gy < 50% were achieved in 98% of the patients. 
V40 Gy < 55% was achieved only in 54% of the patients. Bladder 
constraints including V80 Gy < 15%, V75 Gy < 25% and V70 Gy < 
35% were achieved in all patients. However, V65 Gy < 50% and 
V40 Gy < 70 % were achieved in 96% of the patients. Mean dose 
of < 50Gy for Penile bulb was achieved in only 74% of patients. 
Femoral head tolerance (V53 Gy < 5%) was met in all patients. 
Bowel DVH of V45 Gy < 195 cc was met for most of the patients. 
However, contouring differed between radiation oncologists for 
the bowel. 
Conclusions: Rectal dose constraints to decrease the probability 
of rectal toxicity have been based on a number of studies. 
Although these constraints are not achievable in a significant 
number of patients, stringent parameters have been put forward 
with the intention of decreasing rectal toxicity. Confounding 
variables make interpretation of data with these stringent 
parameters difficult. Recent RTOG studies have not included 
stringent parameters of V40Gy < 55%. More studies need to be 
done to determine if this stringent parameter can be omitted 
altogether. 
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Purpose: Dose escalation of non-small cell lung cancer is 
typically limited by increasing risk of severe adverse events, 
including radiation pneumonitis (RP). Recent studies have 
demonstrated a relationship between a CBCT derived marker 
(CDM) and lung density changes on follow up imaging. This study 
investigates the relationship between a density-based CBCT 
image marker and symptomatic radiation pneumonitis. 
Methods and Materials: CDMs were extracted for NSCLC patients 
treated definitively (> 54 Gy) with fractionated radiotherapy 
between 2011 and 2013. The CDM was defined as the proportion 
of normal lung voxels receiving 20-60 Gy that demonstrated an 
intensity increase between the first and tenth fraction CBCT, as 
previously described. Only voxels with an intensity change 
greater than a defined noise threshold were included. All images 
were registered into a common volume using an intensity-based 
deformable image registration algorithm in the Elastix toolbox. 
All other image analysis was implemented in Matlab 2010b. RP 
was determined from prospective clinical records and reviewed 
retrospectively from the electronic patient record, as scored by 
the treating oncologists at follow up visits as per CTCAE v 4.0. 
Dosimetric parameters extracted included mean lung dose and 
volume of lung receiving 20 Gy (V20). Correlation of dosimetric 
parameters and the CDM to RP events was assessed by 
Spearman’s rank correlation coefficient and multivariate 
logistical regression.  
Results: After excluding patients without dose or CBCT objects, 
65 patients were identified and CDM extracted. In those patients, 
the prescription dose range was 54-74 Gy, mean lung dose range 
was 13-23 Gy and V20 range was 3.4 – 38%. The number of voxels 
with an intensity change greater than the noise level ranged from 
0-74.5% (mean 5.3%). Symptomatic RP (≥ Grade 2) occurred in 
26.1% of patients of these patients. Spearman's rank correlation 
demonstrated significant association between mean lung dose 
and V20 with symptomatic radiation pneumonitis (p = 0.044 and 
p = 0.036 respectively), whereas the CBCT marker was not 
correlated (p = 0.609). Univariate logistic regression of mean 
lung dose and the CBCT marker was not significantly correlated 
with symptomatic RP (p = 0.090 and p = 0.821 respectively). 
Multivariate logistic regression with mean lung dose and the 
CBCT marker was not significant (p = 0.077). 
Conclusions: One previously described density-related CDM was 
not correlated with RP in this dataset. Further research is 
required to characterize the role of imaging markers in 
predicting radiation pneumonitis. 
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Purpose: Total body irradiation (TBI) is used prior to bone 
marrow transplantation as part of the conditioning regimen in 
selected patients. A linear accelerator based technique has been 
used at our treatment centre, between 2004 and 2015. 
Compensators to account for missing tissue in the head and neck 
and lower leg regions, as well as a lung attenuator for internal 
inhomogeneity resulting from low density lung tissue are 
routinely used. Dose variation within ten percent of the 
prescribed midplane dose is considered acceptable. The purpose 
of this study was to determine whether dose variation was within 
acceptable limits for patients who underwent TBI. 
Methods and Materials: Following chart review, 129 patients 
between June 2004 and August 2015 who received TBI in six 
fractions were included in this study. Patients receiving single 
fraction treatment were excluded. MOSFET dosimetry was used 
to measure surface dose at 4 or 5 locations when patients 
received the first fraction of TBI. Dosimetry was repeated during 
the second fraction for any site with variation greater than ten 
percent, or when MOSFET position was noted to have shifted. 
Statistical analysis on patient data, diagnosis and dosimetry 
measurements was carried out using a Microsoft Excel 
spreadsheet. 
Results: Of the 129 patients who met the inclusion criteria, 50 
were diagnosed with AML, 30 with ALL and 11 with CML. The rest 
of the patients were diagnosed with lymphoma or MDS. The mean 
percent variation in dosimetry ranged between 3.5% and 8.3%. 
The highest variation was found in cheek dosimetry. A high 
percentage of dosimetry readings (85.5%) were within the 
acceptable range. The highest number of individual readings 
outside ± 10% was found at the leg. The median percentage 
variation was low (3.3% to 5.1%) depending on location.  
Conclusions: A retrospective analysis of 129 patients was carried 
out for the period 2004 to 2015. The analysis shows acceptable 
variation in dosimetry within ten percent. The top three 
locations with greatest variation were the cheek, the chest, and 
the leg respectively. We conclude that linear accelerator 
delivered TBI at our centre meets the acceptable limits of dose 
variation for 129 patients over a 10-year period. The reasons for 
variation at particular sites will be discussed. 
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Purpose: The CanMEDS framework defines the core physician 
roles on which specialist medical education in Canada is based. 
The revised CanMEDS 2015 framework introduces “Leader” as a 
new CanMEDS competency. In this study, we identified 
leadership training gaps in radiation oncology residency and 
developed a focused curriculum specific to radiation oncology to 
meet this new competency requirement. 
Methods and Materials: A questionnaire was administered to 
senior residents and recent graduates of a radiation oncology 
residency training program in Canada. Qualitative data regarding 
staff and resident leadership responsibilities, leadership training 
in residency, and any perceived gaps in residency leadership 
training were gathered. Based on identified educational needs, 
a leadership curriculum was developed and administered to 
current radiation oncology residents. 
Results: Following analysis of the qualitative questionnaire data, 
three modules were designed to address the identified gaps in 
radiation oncology residency leadership training. Specifically, 
the modules were developed to increase knowledge and 
execution of different leadership styles, develop skills in 
teamwork and negotiation, and recognize specific leadership 
qualities within each resident. 
Conclusions: In this study, we identified important leadership 
competencies for radiation oncology residents as they transition 
into fellowship and junior consultant positions. To our 
knowledge, this is the first description of a radiation oncology-
specific leadership curriculum designed to meet these needs.  
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Purpose: The use of 3D printing technology to create precise 
anatomical models is well documented. These models are used 
by surgeons to better plan upcoming operations and to save 
valuable operating room time. They are also used to educate 
other members of the health care team, such as residents, 
medical students and nurses. However, the use of these 
anatomically accurate models to educate patients in the clinical 
setting has been underutilized. At our centre, we are using 3D 
printer technology to generate accurate clinical models of 
mandibles. Our objective is to use these models to better 
